Thursday, 28 November 2024

 

NanoInnovation 2016 - The Story


(the file video is available under the download menu)

 

TS.VI.C.3

Nanoparticles for therapy of Alzheimer disease

Massimo MASSERINI, Università di Milano-Bicocca - Amypopharma

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by the β-amyloid (Aβ) peptide accumulation and deposition in the brain. Aβ alterations are thought to take place decades before the appearance of the first signs of dementia: this preclinical phase is considered the most promising period for successful disease-modifying therapies, which are still lacking. Since negatively charged lipids showed high binding affinity toward Aβ peptide and low-density lipoprotein-receptor was observed to be present at the blood-brain barrier,

We designed and patented liposomes functionalized with phosphatidic acid and with a modified peptide derived from apolipoprotein-E (mApoE-PA-LIP) potentially able to enter the brain and disaggregate Aβ aggregates both in vitro and in vivo. We  evaluated the possibility to use mApoE-PA-LIP for threatment of AD  on different Tg rodent models of the disease, namely APP/PS1 or APP23 mice.

The  data obtained in vivo  suggest that mApoE-PA-LIP is able either to promote the decrease  of  brain Aβ burden and the amelioration of memory impairment in “old” Tg mice upon acute treatment,  or to slow down brain Aβ accumulation and memory impairment in “young” upon long term treatment.  Together, these data indicate mApoE-PA-LIP as a new nanothecnological device potentially suitable for AD treatment. 

 
Back to TS.VI.C

, SCIENTIFIC PATRONAGE

 


  NANOINNOVATION'S GOT TALENT

 
call for young researchers
by BRACCO FOUNDATION

 

 

, INSTITUTIONAL PATRONAGE





  INSTITUTIONAL PARTNERS

 

    

 

  CORPORATE PARTNERS

     

 

Technical Support

Privacy

Organizing Secretariat

Dr. Cristina Gippa

+ 39 339 771 4107
+ 39 388 1785318
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Federica Lodato

+ 39 335 7253927
+ 39   06 8848831
This email address is being protected from spambots. You need JavaScript enabled to view it.